Eloralintide Side Effects: What Studies Report

Eloralintide in one paragraph

Eloralintide, also identified in the literature as LY3841136, was described as a selective, long-acting amylin receptor agonist developed for the treatment of obesity, with its discovery programme and first clinical proof of concept reported together in a 2025 Molecular Metabolism paper (PMID 41109426). Unlike dual amylin–calcitonin receptor agonists and unlike incretin-based agents, eloralintide was characterised as selective for the amylin receptor, a design choice reviews have linked to expectations about its tolerability profile (PMID 42452898). This page deals only with what the published record says about safety and adverse events; the mechanism, pharmacology and trial-design background are covered separately in the eloralintide course.

Where the safety data came from

Phase 1 proof of concept

A phase 1 proof-of-concept report published in Diabetes, Obesity & Metabolism evaluated eloralintide in adults and described it as a selective, long-acting amylin receptor agonist advanced through early clinical testing, with the authors reporting on safety, tolerability and body-weight effects in that setting (PMID 41559929). The same early clinical proof-of-concept data set was also summarised alongside the preclinical discovery work (PMID 41109426). Early-phase studies of this kind were conducted under trial monitoring, and researchers used them primarily to characterise tolerability across ascending exposures rather than to establish long-term risk.

The 48-week phase 2 trial

The largest published human data set is a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial of eloralintide reported in The Lancet in 2025 (PMID 41207310). That study compared weekly subcutaneous eloralintide with placebo in adults and reported both body-weight outcomes and adverse-event findings over the 48-week period (PMID 41207310). Because it was placebo-controlled, the trial allowed researchers to describe which events occurred more often on active treatment than on placebo, which is the key distinction when interpreting any adverse-event list.

Reviews and pooled analyses

Several 2026 reviews and one network meta-analysis placed eloralintide within the wider amylin-based drug class. A Peptides review surveyed long-acting amylin-related peptides as therapies for obesity and type 2 diabetes (PMID 41747885). A Pharmacological Research review framed amylin-based pharmacotherapy explicitly as part of the search for better-tolerated weight-loss drugs beyond GLP-1 agents (PMID 42586227). A Diabetes, Obesity & Metabolism review compiled experimental data and early-phase clinical trials across the amylin analogue class (PMID 42452898), and a perspectives article in Metabolism Open discussed multi-receptor agonists and next-generation metabolic modulators including their controversies (PMID 41948476). A network meta-analysis in Endocrinology, Diabetes & Metabolism compared novel amylin-based therapies for weight management in adults with overweight or obesity without diabetes (PMID 42175595).

Gastrointestinal Events: What Studies Report

Across the eloralintide literature, gastrointestinal complaints are the adverse-event category that receives the most attention. The 48-week phase 2 trial reported gastrointestinal adverse events, including nausea and vomiting, as the events most commonly observed with eloralintide, and researchers characterised them as predominantly mild to moderate in severity (PMID 41207310). The phase 1 proof-of-concept report similarly focused on tolerability and gastrointestinal events when describing the safety profile of ascending eloralintide exposures in adults (PMID 41559929).

This emphasis is not accidental. Reviews of the amylin class noted that nausea has historically been the limiting adverse effect for amylin-based agents, and that reducing gastrointestinal burden relative to incretin-based therapy is one of the stated goals of newer selective amylin receptor agonists (PMID 42586227). The Diabetes, Obesity & Metabolism review of experimental data and early-phase trials likewise discussed gastrointestinal tolerability as a central comparison point across amylin analogues (PMID 42452898). Readers should note that "mild to moderate" in trial reporting is an investigator-graded severity category, not a statement about how any individual participant experienced an event.

Overall Tolerability and Study Discontinuation: What Studies Report

The phase 2 publication reported safety and tolerability as part of its 48-week placebo-controlled design, allowing researchers to describe treatment-emergent events and treatment discontinuation in the eloralintide groups against placebo (PMID 41207310). The phase 1 report described eloralintide as advancing through early clinical testing with a tolerability profile the authors considered supportive of further development (PMID 41559929). Review authors summarising the class described dose escalation as a standard design feature used in amylin-analogue trials to manage gastrointestinal events (PMID 41747885). Exact event rates, discontinuation percentages and per-dose breakdowns are reported in the primary trial publications themselves rather than reproduced here.

Weight, Appetite and Related Physiological Effects: What Studies Report

Adverse events cannot be read in isolation from the intended pharmacology. Researchers reported reductions in body weight with eloralintide relative to placebo over 48 weeks in the phase 2 trial (PMID 41207310), and the phase 1 proof-of-concept report described body-weight effects consistent with amylin receptor agonism (PMID 41559929). The network meta-analysis compared weight-management outcomes across novel amylin-based therapies in adults with overweight or obesity without diabetes (PMID 42175595). Preclinical and translational work reported that amylin receptor agonism reduces food intake, which is the mechanism reviews connect to both the weight effect and to nausea-type events (PMID 41109426). Consequences of substantial weight reduction — including changes in body composition and nutritional status — were discussed at class level in obesity-pharmacotherapy reviews rather than resolved for eloralintide specifically (PMID 41948476).

Cardiovascular Signals: What Studies Report

A 2026 Cardiology in Review article examined cardiometabolic risk reduction through selective amylin receptor agonism and discussed the emerging cardiovascular implications of eloralintide (PMID 42745233). That article was a review of an early evidence base, not a cardiovascular outcome trial, and its authors framed cardiovascular effects as an emerging rather than an established area for this compound (PMID 42745233). The perspectives paper in Metabolism Open similarly treated cardiometabolic claims for next-generation metabolic modulators as an area of ongoing debate (PMID 41948476). No dedicated cardiovascular-outcome trial of eloralintide appears in the verified literature summarised on this page.

Reported findings at a glance

What the literature does not yet establish

Stating an absence plainly matters as much as summarising a finding. Within the verified literature covered here, the following are not established for eloralintide:

• Multi-year safety. The longest published randomised exposure is the 48-week phase 2 trial (PMID 41207310); no longer controlled data set appears.
• Cardiovascular outcomes. Cardiovascular implications were reviewed as emerging, not demonstrated in an outcome trial (PMID 42745233).
• Special populations. The class reviews and the network meta-analysis addressed adults with overweight or obesity, with the meta-analysis specifying adults without diabetes (PMID 42175595); paediatric, pregnancy and lactation safety data for eloralintide are absent from this literature.
• Rare and post-marketing events. Because eloralintide remained investigational in the published record (PMID 41207310), no post-marketing surveillance data set exists to capture uncommon events that randomised trials of this size cannot detect.
• Direct head-to-head tolerability versus incretin drugs. Reviews discussed the hypothesis that amylin-based agents may be better tolerated (PMID 42586227), and pooled indirect comparisons have been published (PMID 42175595), but indirect comparison is not the same as a direct trial.
• Combination-therapy safety. Multi-receptor and combination strategies were discussed at concept level in obesity-pharmacotherapy perspectives (PMID 41948476) rather than resolved as eloralintide safety data.

Regulatory and access context

Eloralintide was reported in the literature as an investigational compound progressing through phase 1 and phase 2 clinical development (PMID 41559929, PMID 41207310). An investigational status means no regulator has reviewed a marketing application's full safety dossier, and that every adverse-event description available comes from monitored clinical trials with eligibility criteria, dose escalation schedules and laboratory follow-up. Material labelled "research use only" is not a medicine and carries no such monitoring; nothing in the published literature characterises safety outside a clinical trial setting.

How to read an adverse-event list without over-reading it

Three interpretive cautions apply to everything above. First, trial adverse-event tables record events that occurred during treatment, not events proven to be caused by treatment — which is why placebo comparison is the anchor, as in the 48-week phase 2 design (PMID 41207310). Second, early-phase studies are sized to detect common events, so the phase 1 report cannot speak to rare risks (PMID 41559929). Third, narrative reviews synthesise and interpret; they generate expectations about class tolerability rather than new safety evidence (PMID 42452898, PMID 41747885).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or investigational compound. It summarises what researchers reported in the cited publications and does not recommend, endorse or describe use of eloralintide by any person.

References

• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
• Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (Lancet, 2025)
• Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept (Diabetes, Obesity & Metabolism, 2026)
• Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes (Peptides, 2026)
• Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies (Metabolism Open, 2026)
• Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials (Diabetes, Obesity & Metabolism, 2026)
• Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs (Pharmacological Research, 2026)
• Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis (Endocrinology, Diabetes & Metabolism, 2026)
• Cardiometabolic Risk Reduction Through Selective Amylin Receptor Agonism: Emerging Cardiovascular Implications of Eloralintide (Cardiology in Review, 2026)